Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing innovative treatments for prostate cancer, women’s health and other endocrine diseases. Relugolix, an oral once-daily GnRH receptor antagonist, is in Phase 3 development for the treatment of advanced prostate cancer. Top-line Phase 3 results are expected in 2019.